Long-term survival analysis of adjuvant chemotherapy with or without trastuzumab in patients with T1, node-negative HER2-positive breast cancer.

CONCLUSIONS: Adjuvant chemotherapy plus trastuzumab should be recommended for patients with pT1N0M0 HER2+ BC ≥0.8 cm in diameter; adjuvant therapy may not be necessary for tumors <0.8 cm. PMID: 31515457 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31515457?dopt=Abstract

Source: Clinical Cancer Research - September 11, 2019 Category: Cancer & Oncology Authors: He X, Ji J, Tian M, Esteva FJ, Hortobagyi GN, Yeung SJ Tags: Clin Cancer Res Source Type: research